Showing 2151-2160 of 3163 results for "".
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- FDA Approves Galderma's Aklief (trifarotene) Cream for Acnehttps://practicaldermatology.com/news/fda-approves-galdermas-aklief-trifarotene-cream-for-acne/2460164/The FDA has approved Galderma's Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Aklief Cream is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. Trifarotene is the first new retinoid molecule to
- Industry News: Galderma Will Go It Alonehttps://practicaldermatology.com/news/industry-news-galderma-will-go-it-alone/2460161/It’s official. Galderma is going it alone after completion of CHF 10.2 billion acquisition of Nestlé Skin Health, first announced in May 2019. The acquisition, led by a consortium comprising the EQT VIII fund (“EQT”), Luxinva (a wholly-owned subsidiary of
- Skin Cancer Foundation Website Has a New Lookhttps://practicaldermatology.com/news/skin-cancer-foundation-website-has-a-new-look/2460148/The Skin Cancer Foundation’s website has a new look. The site is redesigned to ease navigation and provide visitors with an improved user experience. Nearly 9 million people visit SkinCancer.org annually, and the organization say
- Aczone 7.5% Gel Now Approved Down to Age 9https://practicaldermatology.com/news/aczone-75-gel-now-approved-down-to-age-9/2460144/The FDA has approved the expanded indication for Almirall’s Aczone® 7.5% Gel to include patients aged 9-11. Aczone 7.5% Gel was previously approved in February 2016 to treat inflammatory and non-inflammatory acne in patients 12 and older. The expanded approval was based
- FDA Approves Juvéderm Voluma XC For Mid-Face Injection Via Cannulahttps://practicaldermatology.com/news/fda-approves-juvederm-voluma-xc-for-mid-face-injection-via-cannula/2460137/Allergan’s Juvéderm Voluma XC is now U.S. Food and Drug Administration (FDA)-approved for cheek augmentation in the mid-face in adults over 21 with a TSK Steriglide cannula. This cannula features a patented tip design with a near-tip delivery port for precise product p
- ACS Study: Skin Creams Aren’t What We Thought They Werehttps://practicaldermatology.com/news/acs-study-skin-creams-arent-what-we-thought-they-were/2460136/Researchers report the first direct glimpse of how a skin cream or lotion is structured on the molecular scale, and it’s not quite what they expected. They presented their results at the American Chemical Society (ACS) Fall 2019 National Meeting & Exposition in San Diego.
- Lilly’s Oral JAK Inhibitor Plus Steroids Improves AD Symptomshttps://practicaldermatology.com/news/lillys-oral-jak-inhibitor-plus-steroids-improves-ad-symptoms/2460134/Adding the oral JAK inhibitor baricitinib to standard-of-care topical corticosteroids significantly improved atopic dermatitis disease severity, measured by the validated Investigator's Global Assessment for AD (vIGA) score of "clear or almost clear" skin (vIGA 0, 1), the primary en
- Europe Grants DefenAge Skincare Master Patenthttps://practicaldermatology.com/news/europe-grants-defenage-skincare-master-patent/2460132/DefenAge Skincare now has a master patent from the European Patent Office that covers DefenAge’s core technology. The patent protects the exclusive rights of DefenAge to use the spectrum of immune peptides called defensins in topical cosmetic formulations in a specific range of co
- Soliton Treats First Patients in Cellulite Trialhttps://practicaldermatology.com/news/soliton-treats-first-patients-in-cellulite-trial/2460124/The first patients in Soliton’s cellulite trial have been treated, the Company reports. "Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of Soliton, in a ne